SCHEMBL26985201

SCHEMBL26985201

COCCOc1cc(N)ccc1C(=O)OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.55
CYP1A2 P05177 2/20 0.52
CYP2D6 P10635 1/20 0.52
SCN1A P35498 1/20 0.52
SCN2A Q99250 1/20 0.52
SCN3A Q9NY46 1/20 0.52
ALDH1A1 P00352 6/20 0.47
TDP1 Q9NUW8 2/20 0.46
MAPT P10636 6/20 0.44
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 3/20 0.44
HPGD P15428 3/20 0.44
GLA P06280 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
ATM Q13315 1/20 0.44
ABL1 P00519 1/20 0.43
HSP90AA1 P07900 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6829337 0.88 GAA (0.55) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL15295021 0.88 CYP1A2 (0.59) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL26640241 0.88 GAA (0.51) GAACYP1A2ALDH1A1MAPTKDM4E
SCHEMBL2124146 0.87 GAA (0.54) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL384675 0.84 MAPT (0.53) CYP1A2ALDH1A1TDP1MAPTKDM4E
SCHEMBL2337419 0.84 TDP1 (0.62) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL31107344 0.84 CYP1A2 (0.55) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL20982560 0.83 MAPT (0.56) GAAALDH1A1TDP1MAPTKDM4E
SCHEMBL1734232 0.82 CYP2D6 (0.73) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL25344842 0.82 FFAR4 (0.57) CYP1A2CYP2D6ALDH1A1TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353862-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-11-20 US disclosed
EP-4547671-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2025-05-07 EP disclosed
WO-2024010761-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 WO disclosed
WO-2024010761-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353862-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 GAA 3895/4885CYP1A2 4806/4885CYP2D6 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.